PCSK9 inhibitor for people with diabetes and at very high CV risk, with persistently high LDL-C levels, despite having statin therapy (maximum tolerated dose) combined with ezetimibe, or having statin intolerance. This evidence concerns the gene PCSK9 and diabetes mellitus.